WO2012066347A1 - Formulations à base d'huile - Google Patents

Formulations à base d'huile Download PDF

Info

Publication number
WO2012066347A1
WO2012066347A1 PCT/GB2011/052262 GB2011052262W WO2012066347A1 WO 2012066347 A1 WO2012066347 A1 WO 2012066347A1 GB 2011052262 W GB2011052262 W GB 2011052262W WO 2012066347 A1 WO2012066347 A1 WO 2012066347A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
pharmaceutical composition
prodrug
group
alkyl
Prior art date
Application number
PCT/GB2011/052262
Other languages
English (en)
Inventor
Richard Franklin
Bernard Golding
Original Assignee
Shire, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire, Llc filed Critical Shire, Llc
Publication of WO2012066347A1 publication Critical patent/WO2012066347A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals

Definitions

  • the present invention relates to the use of oil based delivery vehicles to prevent undesirable premature hydrolysis of phenolic amino benzoic acid carbamate prodrugs, while resident in the gut lumen.
  • Preclusion of water and hydrolytic enzymes prior to prodrug absorption ensures that such compounds can be fully absorbed intact without undergoing unintended premature hydrolysis in the gastrointestinal tract so maximizing the benefit of improved systemic availability afforded by the prodrug.
  • judicious selection of oil and prodrug salt form can result in a sustained release plasma PK profile. The avoidance of premature degradation and release of active drug into the gut lumen minimizes any potential for a direct adverse interaction within the gut lumen.
  • prodrugs - biologically reversible, derivatised drugs - offer the potential for real advantage over the parent drug in a number of ways.
  • Prodrugs may improve the systemic delivery of the parent drug which might otherwise be compromised by incomplete absorption from the gut.
  • oral absorption of the important antiviral agent acyclovir is normally very poor (15-30%) due to its poor solubility but the use of the valine ester prodrug valacyclovir ensures much improved, 2-5-fold, absorption due to it facilitated active transport (Weller S et al (1993) Clin Pharmacol Ther 54 595-605).
  • prodrugs Another potential benefit to the use of prodrugs is avoidance of initial high first pass metabolism in the gut wall or liver.
  • acetyl salicylate or anthranilic acid esters has been shown to be of value in improving the oral bioavailability of drugs such as naltrexone (Hussain MA & Shefter E (1988) Pharm Res. 5, 1 13-5) and oestradiol (Hussain MA et al, (1988) Pharm Res. 5, 44-47).
  • naltrexone Humanssain MA & Shefter E (1988) Pharm Res. 5, 1 13-5
  • oestradiol Humanssain MA et al, (1988) Pharm Res. 5, 44-47.
  • this approach is susceptible to unwanted premature ester hydrolysis in the gut lumen reducing the amount of "protected drug" available for absorption and capable of delivering active to the systemic circulation.
  • inactivated benzoyl ester prodrug of galantamine Memogain® is claimed to reduce the incidence of locally mediated emesis normally associated with the parent drug (Maelicke A et al (2010) J Mol Neurosci 40, 135-137).
  • premature gut luminal hydrolysis of this ester could make available some of the active drug potentially capable of eliciting an unwanted direct action on the gut.
  • Prodrugs are, by definition, biologically and/or chemical unstable but as mentioned above this should ideally not occur in the gut lumen as this will reduce the amount of protected or absorbable prodrug available and may result in active drug adversely affecting the gut. Generation of the active drug should only occur after absorption, in the liver or systemic circulation and not in the gut. If chemical hydrolysis plays a predominant role in the release of the active, as for example in the cleavage of the ester prodrug of valacyclovir, this has the potential to significantly contribute to premature gut luminal hydrolysis.
  • Amino benzoic acid carbamates may represent a useful class of non toxic prodrugging moieties, but which are very susceptible to such premature chemical hydrolysis. This propensity to chemical (pH dependent) hydrolysis is due to the labilising influence of the closeness of the aromatic ring to the carbamate nitrogen. If this problem could be overcome, the full potential of this and other chemically and/or biologically labile prodrugging moieties could be exploited.
  • the present invention affords a means of avoiding premature gut luminal degradation via chemical or enzymic cleavage to the active drug molecule and any unwanted consequences e.g. loss of absorbable intact prodrug and/or adverse Gl events.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising: (a) an amino benzoic acid carbamate prodrug of an approved therapeutically active compound including one or more phenolic groups, its pharmaceutically acceptable salts, pharmaceutically acceptable esters or pharmaceutically acceptable salts of esters; and (b) a pharmaceutically acceptable oil-based delivery vehicle.
  • the present invention provides a pharmaceutical composition of the first aspect of the use as a medicament.
  • the present invention provides a use of an oil-based delivery vehicle to prevent hydrolysis of an amino benzoic acid prodrug of an approved therapeutically active compound including one or more phenolic groups.
  • the present invention provides a use of an oil-based delivery vehicle to preserve the chemical integrity of amino benzoic acid prodrugs of phenolic pharmaceuticals to enable their active transport/absorption from the Gl tract.
  • Figure 1 illustrates the plasma buprenorphine concentrations versus time after various formulations of buprenorphine PABA carbamate given orally to monkeys.
  • Figure 2 Plasma meptazinol concentrations versus time after various formulations of meptazinol PABA carbamate given orally to monkeys.
  • delivery vehicle refers to a component in which an active compound is dispersed or dissolved.
  • the pharmaceutical compositions of the invention may contain combinations of more than one delivery vehicle.
  • Such delivery vehicles can be oils, including those of petroleum, animal, vegetable or synthetic origin.
  • oil-based means that the delivery vehicle is substantially oil. Other components may be present as excipients, but the bulk of the delivery vehicle is oil. The delivery vehicle is thus substantially free of water.
  • pharmaceutically acceptable refers to molecular entities and compositions that are generally regarded as safe.
  • pharmaceutically acceptable delivery vehicles used in the practice of this invention are physiologically tolerable and do not typically produce an allergic or similar untoward reaction (for example, gastric upset, dizziness and the like) when administered to a patient.
  • pharmaceutically acceptable means approved by a regulatory agency of the appropriate governmental agency or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.
  • active compound unless specifically indicated, is to be understood as referring to the drug portion of a prodrug of the present invention, as described herein.
  • salts can include acid addition salts or addition salts of free bases.
  • Suitable pharmaceutically acceptable salts include, but are not limited to, metal salts such as sodium potassium and cesium salts; alkaline earth metal salts such as calcium and magnesium salts; organic amine salts such as triethylamine, guanidine and N-substituted guanidine salts, acetamidine and /v-substituted acetamidine, pyridine, picoline, ethanolamine, triethanolamine, dicyclohexylamine, and ⁇ , ⁇ '-dibenzylethylenediamine salts.
  • metal salts such as sodium potassium and cesium salts
  • alkaline earth metal salts such as calcium and magnesium salts
  • organic amine salts such as triethylamine, guanidine and N-substituted guanidine salts, acetamidine and /v-substituted acetamidine, pyridine, picoline, ethanolamine, triethanolamine, dicyclohexylamine, and
  • Pharmaceutically acceptable salts include, but are not limited to inorganic acid salts such as the hydrochloride, hydrobromide, sulfate, phosphate; organic acid salts such as trifluoroacetate and maleate salts; sulfonates such as methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, camphor sulfonate and naphthalenesulfonate; and amino acid salts such as arginate, gluconate, galacturonate, alaninate, asparginate and glutamate salts (see, for example, Berge, ef al. "Pharmaceutical Salts," J. Pharma. Sci. 1977; 66: 1 ).
  • inorganic acid salts such as the hydrochloride, hydrobromide, sulfate, phosphate
  • organic acid salts such as trifluoroacetate and maleate salts
  • Hydrophile-Lipophile Balance is an empirical expression of the relationship of the hydrophilic ("water-loving") and hydrophobic ("water-hating") groups of an oil.
  • HLB Hydrophile-Lipophile Balance
  • soft gelatin dosage unit is intended to encompass any dosage unit and/or form which employs a gelatin or non animal alternative casing. Numerous casing materials have been proposed for soft capsules including gums, carrageenans, hydroxypropylated starches, celluloses, and the like. As used herein, the term “soft gelatin dosage unit” means a dosage form constructed of mammalian gelatin, fish gelatin, gums, guars, carrageenans, modified starches and the like.
  • elixir herein refers to is a flavored sweet oily liquid in which the prodrug is dissolved or suspended.
  • Micron isation is defined as the process by which a material is reduced in size, often to micrometer proportions. Typically micronised pharmaceutical products may have a particle size ranging from 0.1 to 10.0 ⁇ [027] Compositions of the invention
  • the amino benzoic acid carbamate prodrug has a structure:
  • drug means a drug having a phenolic group
  • R is independently selected at each occurance from the group consisting of: hydroxy, carboxy, acetyl, cyano, cyanomethyl, nitro, amino, halogen (e.g. fluoro, chloro or bromo), Ci_ 6 alkyl (e.g. methyl, ethyl or propyl), Ci_ 6 haloalkyl (e.g. trifluoromethyl), d. 6 alkoxy (e.g. methoxy, ethoxy or propoxy), Ci_ 6 haloalkoxy (e.g. trifluoromethoxy), C 3 . 6 cycloalkyl (e.g. cyclohexyl), aryl (e.g. phenyl), aryl-Ci_ 6 alkyl (e.g. benzyl) or Ci_ 6 alkyl aryl;
  • halogen e.g. fluoro, chloro or bromo
  • Ci_ 6 alkyl e.g. methyl,
  • R' is selected from the group consisting of: H and C-i_ 6 alkyl (e.g. methyl, ethyl or propyl); and n is from 0 to 3; or a pharmaceutically acceptable salt thereof.
  • n is from 0 to 2. Preferably, n is 0 or 1.
  • R is -OH.
  • R' is selected from the group consisting of: H, Me and Et. Preferably, R' is H.
  • -COOR' is para- to the -NH- group. In an embodiment, - COOR' is meta- to the -NH- group.
  • the pharmaceutical composition is in unit dosage form.
  • the amount of the oil in the oil based delivery system is sufficient to dissolve or at least partially dissolve the prodrug.
  • the pharmaceutical composition further comprises pharmaceutically suitable anti-oxidants/stabilisers and/or surfactants and/or preservatives.
  • the purpose of the surfactant is to facilitate dissolution of the prodrug salt in the delivery vehicle.
  • the pharmaceutical composition further comprises a pharmaceutically ingestible containment system or other delivery system for oily formulations.
  • the phenolic drug is a phenolic opioid drug.
  • phenolic opioid drugs include: buprenorphine, butorphanol, dezocine, hydromorphone, ketobemidone, levorphanol, meptazinol, morphine, nalbuphine, nalorphine, naloxone, oxymorphone, pentazocine and tapentadol.
  • the phenolic drug is a non-opioid phenolic drug.
  • non-opioid phenolic drugs include: apomorphine, curcumin, fenretinide, dextrorphan, L-dopa, dronabinol ( ⁇ 9 tetrahydrocannibinol), nabilone, oestriol, oestradiol, oestrone, raloxifene, rotigotine, and resveratrol.
  • the drug may contain more than phenolic hydroxyl group.
  • the prodrug of the invention has only a single amino benzoic acid carbamate group conjugated to the drug molecule.
  • the present invention embraces any possible position of substitution by the amino benzoic acid carbamate group on the drug molecule.
  • the position of prodrugging conjugation with the amino benzoic acid is that normally susceptible to first pass metabolism and/or nearest the pharmacophoric region (when that is known).
  • additional prodrugging moieties may be present at other phenolic positions within the drug molecule.
  • the amino benzoic acid portion of the carbamate prodrug of the present invention is selected from the group comprising: para-amino benzoic acid, 4-amino acid salicylic acid and 5-amino salicylic acid.
  • the pharmaceutically acceptable salt of these drugs may be selected from a wide range embracing differing hydro/lipophilicities and would include but is not restricted hydrophilic salts such as hydrochloride, hydrobromide, maleate, and trifluoroacetate and lipophilic salts such as camphor sulphonate, naphthalene sulphonate, and toluene sulphonate.
  • the pharmaceutically acceptable oils of the oil-based delivery vehicle can be selected from a wide spectrum oils of differing hydro/lipophilicities as defined by their hydrophilic - lipophilic balance (HLB) values.
  • the pharmaceutically acceptable oil is selected from the group comprising: almond oil, canola oil, castor oil, cotton seed oil, corn oil, (fractionated) coconut oil, olive oil, peanut oil (arachis oil), sesame seed oil, sunflower oil, medium chain mono and diglycerides, hydrogenated vegetable oil, medium chain triglycerides, mineral oil, a tocopherol, capric or caprylic triglycerides and glycerol stearate.
  • the pharmaceutically acceptable oil is Gelucire 44/14® (Gelucire 44/14® is available from the company Gattefosse; is a lauroyi macrogol-32 glyceride EP / lauroyi polyoxyl-32 glyceride NF; is a non-ionic water dispersible surfactant composed of well-characterized PEG-esters, a small glyceride fraction and free PEG).
  • the pharmaceutically acceptable oil is selected from the group comprising: cotton seed oil, peanut oil, Capmul®, Miglyol® 810 or 812 and combinations thereof.
  • a fuller list of pharmaceutically acceptable oils can be found in the "Handbook of Pharmaceuticals Excipients" edited by Rowe RC, Sheskey PJ, and Weller PJ, Pharmaceutical Press 2003.
  • the pharmaceutically acceptable anti-oxidant is selected from the group comprising: butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), monothioglycerol, ethylene diamine tetra acetic acid (EDTA), thiourea and tocopherol.
  • the surfactant is selected from the group comprising: lecithin, various phospholipids, polysorbate (e.g. Tween® such as Tween® 20, 40 or 80), polyethylene castor oils (e.g. Cremphor® EL) and polyethylene glycols (e.g. PEG 400).
  • the surfactant includes a sorbitan fatty acid ester (SPAN) which is a non-ionic surfactant. SPANs offer greater viscosity than surfactants such as Tween and thereby may provide better suspending properties.
  • SPAN sorbitan fatty acid ester
  • the surfactant is included in the pharmaceutical composition at a range of from about 0.1 % to about 15% w/w, preferably from about 5% to about 15% w/w.
  • the surfactant minimises the risk of particle aggregation in the formulation suspension.
  • the pharmaceutically acceptable oil of the pharmaceutical composition is selected from the group consisting of: Miglyol® 810, Miglyol® 812 and Gelucire 44/14®; the pharmaceutical composition comprises a surfactant selected from the group consisting of: Tween® 20, 40 and 80; and the surfactant included in the pharmaceutical composition is in the range of from about 5% to about 15% w/w.
  • the pharmaceutical composition is contained in a soft or hard gelatin capsule.
  • the pharmaceutical composition is contained in a soft gelatin capsule.
  • the gelatin capsule is a size zero soft gelatin capsule.
  • Non gelatin alternatives include agar-agar (a seaweed), carrageenan, pectin, and konjak.
  • the pharmaceutical composition is contained in a tablet with a porous matrix. Examples of porous matrices include Neusilin® (a magnesium aluminometasilicate), Fujicalin® (a dibasic anhydrous calcium phosphate) or porous hydroxyapatite. The porous matrix facilitates the incorporation of oils.
  • the pharmaceutical composition of the present invention may simply be administered as a measured volume elixir.
  • the prodrugs of the present inventions are meptazinol amino benzoic acid carbamate, buprenorphine amino benzoic acid carbamate, butorphanol amino benzoic acid carbamate, dezocine amino benzoic acid carbamate, hydromorphone amino benzoic acid carbamate, ketobemidone amino benzoic acid carbamate, levorphanol amino benzoic acid carbamate, morphine amino benzoic acid carbamate, nalbuphine amino benzoic acid carbamate, naloxone amino benzoic acid carbamate, nalorphine amino benzoic acid carbamate, oxymorphone amino benzoic acid carbamate, pentazocine amino benzoic acid carbamate, tapentadol amino benzoic acid carbamate.
  • Non-opioid prodrugs include apomorphine amino benzoic acid carbamate (mono or di), curcumin amino benzoic acid carbamate, L-dopa (mono or di) amino benzoic acid carbamate, dronabinol amino benzoic acid carbamate, dextrorphan amino benzoic acid carbamate, fenretinide amino benzoic acid carbamate, oestradiol amino benzoic acid carbamate, oestriol amino benzoic acid carbamate, oestrone amino benzoic acid carbamate, nabilone amino benzoic acid carbamate, raloxifene amino benzoic acid carbamate, rotigotine amino benzoic acid carbamate, or resveratrol amino benzoic acid carbamate.
  • the prodrugs are presented as their free base/acids, hydrochloride, hydrobromide, maleate, trifluoroacetate, camphor sulphonate, naphthalene sulphonate, toluene sulphonate or other appropriate salts.
  • the formulation comprises 100% refined cotton seed oil containing dissolved or suspended prodrug in a suitable salt or free base/acid form.
  • the specification for refined cotton seed oil can be found in the US National Formulary monograph and typically contains; C16:0 fatty acid, 17-29%, C18:1 fatty acid 13-44% and C18 :2 fatty acid, 40-63% as well as minor amount of C14:0,C16: 1 , C18:0, C18:3.
  • the formulation comprises 100% refined peanut oil (approximate HLB value, 6) containing dissolved or suspended prodrug in a suitable salt or free base/acid form.
  • the specification for refined peanut oil can be found in the US National Formulary monograph and typically contains the following fatty acids; C16:0 6- 15.5%, C18: 1 36-72%, C18:2 13-45% with minor amount of C14:0, C16:1 , C18:3, C20:0, C20: 1 , C20:4, C22:0 and C24:0.
  • the formulation comprises 100% Capmul® MCMC-8, EP containing dissolved or suspended prodrug in a suitable salt or free base/acid form.
  • Capmul® MCMC-8, EP can be found in the European Pharmacopeia Monograph for Glycerol Monocaprylate, Type 1. It is a mono-, diglyceride of medium chain fatty acids (mainly caprylic). It is a mixture of monoacylglycerols mainly mono- O-octanoylglycerol containing variable quantities of di-and triacylglycerols, obtained by direct esterification of glycerol with caprylic (octanoic) acid
  • the formulation comprises 100% Miglyol® 810 or 812 (approximate HLB value 1 1 ) containing dissolved or suspended prodrug in a suitable salt or free base/acid form.
  • Miglyol® 810 or 812 contains caprylic and capric triglyceride as defined by the USP National Formulary 22 or European Pharmacopeia for medium-chain triglycerides or the British Pharmacopeia for fractionated coconut oil.
  • Other Miglyols are envisaged and include 818, 829 and 840 neutral oils.
  • Suitable examples of pharmaceutically acceptable preservatives include, but are not limited to, various antibacterial and antifungal agents such as solvents, for example ethanol, propylene glycol, benzyl alcohol, chlorobutanol, quaternary ammonium salts, and parabens (such as methyl paraben, ethyl paraben, propyl paraben, etc.) as well as ascorbic acid.
  • solvents for example ethanol, propylene glycol, benzyl alcohol, chlorobutanol, quaternary ammonium salts
  • parabens such as methyl paraben, ethyl paraben, propyl paraben, etc.
  • pharmaceutical composition is an elixir including a sweetened flavoured oily solution or suspension of the prodrug.
  • Preferred masking flavours include cherry, blueberry, raspberry, backcurrant or strawberry.
  • the use of pharmaceutically acceptable odorants may be required for the elixir compositions and would include, but are not limited to, synthetic aromas and natural aromatic oils such as extracts of oils, flowers, fruits (e.g., banana, apple, sour cherry, peach) and combinations thereof, and similar aromas. Their use depends on many factors, the most important being the organoleptic acceptability for the population that will be taking the pharmaceutical compositions.
  • Suitable examples of pharmaceutically acceptable sweeteners include, but are not limited to, aspartame, saccharin, saccharin sodium, sodium cyclamate, xylitol, mannitol, sorbitol, lactose and sucrose.
  • the prodrug suspension may be one of micronised material of suitable particle size.
  • utilisation of the PepT1 transporter requires the presence of a peptide bond while use of the monocarboxylic acid transporter (MCT) or ceftibuten/fluoroscein transporter requires an aryl carboxylic acid residue.
  • MCT monocarboxylic acid transporter
  • ceftibuten/fluoroscein transporter requires an aryl carboxylic acid residue.
  • Neither of these features is usually present in the parent structures of the preferred drugs under consideration in this present invention. The features are certainly not both present in the parent structures of the preferred drugs under consideration.
  • Utilization of active transport mechanisms enables improved absorption of these prodrugs which could not otherwise be affected by the more usual simple diffusional process.
  • the use of these prodrugs affords transient protection against gut wall and hepatic first pass metabolism, to which the drug itself is normally exposed.
  • the use of a carefully selected oil based formulation ensures minimisation of the aforementioned premature gut luminal hydrolysis and so preserves the chemical integrity of these prodrugs. The
  • a further benefit of this invention is the avoidance of premature release of the active drug in the gut lumen and unwanted interactions with gut opioid or other receptors that may normally bring about unwanted effects e.g. hypomotility and constipation.
  • the phenolic drug is a cytotoxic agent avoidance of the presence of active drug in the gut lumen would serve to limit the nausea, vomiting and diarrhoea associated with the direct cytotoxic actions on the gut epithelial cells.
  • One embodiment of the present invention is a method of treating a disorder in a subject in need thereof.
  • the method comprises orally administering a therapeutically effective amount of a selected prodrug formulation of the present invention to the subject.
  • the disorder may be one treatable with the drug such as pain of varying aetiology (dronabinol and nabilone).
  • the condition may be anyone of a number of diseases such as Parkinsonism (apomophine, L-dopa, rotigotine), osteoporosis and breast cancer (raloxifene) menopausal symptoms (oestradiol, oestrone, oestriol), cancers of a wide diversity (lymphoid, myeloid, multiple myeloma, breast, stomach, prostate, liver, pancreas, colon and thyroid (resveratrol and curcumin) treatable with the formulated prodrugs of the invention.
  • the prodrug formulations encompassed by the present invention may be administered in conjunction with other therapies and/or in combination with other complementary active agents. In such combination therapies, the prodrug formulations encompassed by the present invention may be administered prior to, concurrent with, or subsequent to the other therapy and/or active agent.
  • the present invention is directed to a method for minimizing the unwanted premature chemical and/or enzymic instability of the prodrug in the gut lumen - - and effective loss of absorbable prodrug - normally seen after administration of the unformulated prodrug.
  • the method comprises orally administering a prodrug formulation to a subject in need thereof, wherein the prodrug formulation is comprised a judiciously selected salt form dissolved or suspended in carefully selected oil or oil combination. Where the prodrug is in suspension the particle size is optimal for the desired rate of dissolution and absorption and may, where necessary, be the result of micronization.
  • the present invention is directed to a method for minimising the potential for any direct adverse interactions of the active drug within the gut lumen compared to those seen with use of the unformulated prodrug.
  • the method comprises preparing a prodrug formulation of a judiciously selected salt form dissolved or suspended in a carefully selected oil or oil emulsion. Where the prodrug is in suspension, the particle size is optimal for the desired rate of dissolution and absorption and may, where necessary, be the result of micronization.
  • the present invention is directed to a method for sustaining the delivery of the prodrug compared to that seen with use of the unformulated prodrug.
  • the method comprises preparing a prodrug formulation comprising a judiciously selected salt form dissolved or suspended in a carefully selected oil. Where the prodrug is in suspension the particle size is optimal for the desired rate of dissolution and absorption and may, where necessary, be the result of micronization.
  • the sustainment of plasma active drug concentrations should be at least 20% longer than when the unformulated prodrug administered.
  • compositions of the present invention may be administered as simple elixirs, it is preferable to present the composition appropriately encapsulated in hard or soft gelatin or non-gelatin capsules or incorporated into suitable tablets or caplets.
  • Capsules may be of varying sizes 00-4 and may contain volumes up to ⁇ 1 ml (size 00). Tablets may be of whatever size is deemed likely to be acceptable to the patient.
  • Capsules may be hard or soft gelatin.
  • soft gelatin dosage unit means a dosage form constructed of mammalian gelatin, fish gelatin, gums, guars, carrageenans, or modified (hydroxypropylated) starches.
  • Hard gelatin capsules may be two piece, sealed capsules and, as with soft gelatin, be of any colour (or colourless ) or shape.
  • suitable pharmaceutically acceptable dyes include, but are not limited to, synthetic and natural dyes such as titanium dioxide, beta-carotene and extracts of grapefruit peel.
  • the pharmaceutical compositions of the invention may be incorporated into tablets comprising porous matrices.
  • porous matrices such as Neusilin® (a magnesium aluminometasilicate), Fujicalin® (a dibasic anhydrous calcium phosphate (DCHA) or porous hydroxyapatite facilitate the incorporation of oils.
  • DCHA dibasic anhydrous calcium phosphate
  • porous hydroxyapatite facilitate the incorporation of oils.
  • the use of these materials enables development of free flowing powders of oily compositions that have excellent tablettability.
  • formulations of the present invention can be administered from one to six times daily, depending on the dosage form and dosage.
  • the formulations of the present invention may used in human or veterinary medicine.
  • the invention therefore includes pharmaceutical formulations of the inventions adapted for use in human or veterinary medicine.
  • compositions of the invention may contain from 0.01 to 99% weight per volume of the prodrugs encompassed by the present invention.
  • Appropriate patients to be treated according to the methods of the invention include any human or animal in need of such treatment.
  • Methods for the diagnosis and clinical evaluation of the disease condition including its severity in an animal or human will be well known in the art.
  • the patient is preferably a mammal, more preferably a human, but can be any subject or animal, including a laboratory animal in the context of a clinical trial, screening, or activity experiment employing an animal model.
  • the methods and compositions of the present invention are particularly suited to administration to any animal or subject, particularly a mammal, and including, but not limited to, domestic animals, such as feline or canine subjects, farm animals, such as but not limited to bovine, equine, caprine, ovine, and porcine subjects, research animals, such as mice, rats, rabbits, goats, sheep, pigs, dogs, cats, etc., avian species, such as chickens, turkeys, songbirds, etc.
  • domestic animals such as feline or canine subjects
  • farm animals such as but not limited to bovine, equine, caprine, ovine, and porcine subjects
  • research animals such as mice, rats, rabbits, goats, sheep, pigs, dogs, cats, etc.
  • avian species such as chickens, turkeys, songbirds, etc.
  • a physician will determine the actual dosage which will be most suitable for an individual subject.
  • the specific dose level and frequency of dosage for any particular individual may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual undergoing therapy.
  • a suitable therapeutically effective and safe dosage can be administered to subjects.
  • the daily dosage level of the prodrug formulation may be administered in single or multiple doses.
  • the duration of treatment may be determined by one of ordinary skill in the art, and should reflect the nature of the condition and/or the rate and degree of therapeutic response to the treatment. Typically, a physician will determine the actual dosage which will be most suitable for an individual subject.
  • the prodrug formulations encompassed by the present invention may be administered in conjunction with other therapies and/or in combination with other active agents.
  • the prodrug formulation encompassed by the present invention may be administered to a patient in combination with other active agents used to treat that condition.
  • An active agent to be administered in combination with the prodrug formulation is encompassed by the present invention.
  • the prodrug formulation encompassed by the present invention may be administered prior to, concurrent with, or subsequent to the other therapy and/or active agent.
  • the individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations by any convenient route.
  • administration is sequential, either the prodrug formulation encompassed by the present invention or the second active agent may be administered first.
  • the prodrug formulation encompassed by the present invention may be administered in a sequential manner in a regimen that will provide beneficial effects of the drug combination.
  • the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those of ordinary skill in the art.
  • Example 1 Assessment of chemical/biological stability of buprenorphine PABA carbamate in simulated gastric and intestinal juice
  • buprenorphine PABA carbamate was investigated in what is now considered a more realistic simulated intestinal fluid containing sodium taurocholate and lecithin described as "FaSSIF” (fasted state simulated intestinal fluid) or “FeSSIF” (fed state simulated intestinal fluid).
  • Prodrug stability was initially determined in USP SGF & USP SIF.
  • Prodrug 20ug/ml_ was incubated in USP SGF comprising NaCI 34mM, HCI ⁇ 70nM, pepsin 0.32% (overall pH1 .1 ) for 1 h at 37C or USP SIF composed of monobasic potassium phosphate 0.05M, sodium hydroxide 0.15M and 10% w/v pancreatin ( adjusted to pH 6.8) for 2h at 37°C.
  • USP SIF composed of monobasic potassium phosphate 0.05M, sodium hydroxide 0.15M and 10% w/v pancreatin ( adjusted to pH 6.8) for 2h at 37°C.
  • prodrug and any generated active drug were assayed using a qualified LC-MS/MS method.
  • the stability of the buprenorphine prodrug was assessed by incubation for 2h at 37°C in the more, in vivo, representative FaSSIF cocktail comprising sodium taurocholate 3mM, lecithin 0.75mM, NaOH 8.7mM, NaH 2 P0 4 . H 2 0 28.7mM, NaCI 106mM, pancreatin 1 % (overall pH 6.5). After acidifying the incubation to stop any reaction the amount of prodrug remaining and drug generated were determined using a qualified LC-MS/MS method.
  • the corresponding FeSSIF cocktail was used in comparable manner, and comprised sodium taurocholate 15mM, lecithin 3.75mM, NaOH 101 mM, acetic acid 144mM, and NaCI 202mM (overall pH 5.0). Pancreatin was again added at 1 %. Again remaining prodrug and any generated active drug were assayed using a qualified LC-MS/MS method.
  • Example 2 Comparative effect of various oil formulations of buprenorphine PABA carbamate on the observed pharmacokinetics of resultant buprenorphine in primates
  • meptazinol PABA carbamate was assessed by incubation for 2h at 37°C in a more in vivo representative FaSSIF cocktail comprising sodium taurocholate 3mM, lecithin 0.75mM, NaOH 8.7mM, NaH 2 P0 4 . H 2 0 28.7mM, NaCI 106mM, pancreatin 1 % (overall pH 6.5). After acidifying the incubation to stop any reaction the amount of prodrug remaining and drug generated were determined using a qualified LC-MS/MS method.
  • the corresponding FeSSIF cocktail was employed similarly, and comprised sodium taurocholate 15mM, lecithin 3.75mM, NaOH 101 mM, acetic acid 144mM, and NaCI 202mM (overall pH 5.0). Pancreatin was present at 1 %. Again remaining prodrug and any generated active drug were assayed using a qualified LC-MS/MS method.
  • Example 4 Comparative effect of various oil formulations of meptazinol PABA carbamate on the observed pharmacokinetics of resultant meptazinol in primates
  • Example 5 Comparative effect of a Gelucire oil formulation of meptazinol PABA cabamate on the pharmacokinetics of meptazinol in the cynomolqus monkey.
  • Table 4 Pharmacokinetics of meptazinol in the monkey after oral dosing of 2 mg meptazinol equivalents /kg in Gelucire® or water

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne l'utilisation d'excipients d'administration à base d'huile pour empêcher une hydrolyse prématurée indésirable de promédicaments à base de carbamate d'acide amino benzoïque phénolique, alors qu'ils résident dans la lumière intestinale. La prévention de l'eau et des enzymes hydrolytiques avant l'absorption de promédicament assure que de tels composés peuvent être totalement absorbés en étant intacts sans subir d'hydrolyse prématurée non voulue dans le tractus gastro-intestinal de façon à rendre maximal l'avantage d'une disponibilité systémique améliorée procurée par le promédicament. En outre, une sélection judicieuse d'huile et de forme saline de promédicament peut conduire à un profil pharmacocinétique (PK) dans le plasma à libération entretenue. Le fait d'éviter une dégradation prématurée et une libération prématurée de médicament actif dans la lumière intestinale rend minimal tout potentiel pour une interaction défavorable directe à l'intérieur de la lumière intestinale.
PCT/GB2011/052262 2010-11-18 2011-11-18 Formulations à base d'huile WO2012066347A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1019525.3 2010-11-18
GB201019525A GB201019525D0 (en) 2010-11-18 2010-11-18 Oil-based formulations

Publications (1)

Publication Number Publication Date
WO2012066347A1 true WO2012066347A1 (fr) 2012-05-24

Family

ID=43431636

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/052262 WO2012066347A1 (fr) 2010-11-18 2011-11-18 Formulations à base d'huile

Country Status (2)

Country Link
GB (1) GB201019525D0 (fr)
WO (1) WO2012066347A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019007441A1 (fr) * 2017-07-04 2019-01-10 山东丹红制药有限公司 Suspension à libération prolongée contenant un ester d'analogue de dézocine et son procédé de préparation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063109A2 (fr) * 2004-12-09 2006-06-15 Insys Therapeutics, Inc. Formulations de dronabinol stable a temperature de laboratoire
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
US20100260857A1 (en) * 2009-04-13 2010-10-14 Joan Fallon Enzyme delivery systems and methods of preparation and use
WO2011011766A1 (fr) * 2009-07-23 2011-01-27 Shire Llc Promédicaments à base de l'acide aminé galantamine et de peptides et utilisations de ceux-ci
WO2011133151A1 (fr) * 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprenant des promédicaments opiacés modifiés phénol clivables par enzyme et leurs inhibiteurs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063109A2 (fr) * 2004-12-09 2006-06-15 Insys Therapeutics, Inc. Formulations de dronabinol stable a temperature de laboratoire
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
US20100260857A1 (en) * 2009-04-13 2010-10-14 Joan Fallon Enzyme delivery systems and methods of preparation and use
WO2011011766A1 (fr) * 2009-07-23 2011-01-27 Shire Llc Promédicaments à base de l'acide aminé galantamine et de peptides et utilisations de ceux-ci
WO2011133151A1 (fr) * 2010-04-21 2011-10-27 Pharmacofore, Inc. Compositions comprenant des promédicaments opiacés modifiés phénol clivables par enzyme et leurs inhibiteurs

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BERGE ET AL.: "Pharmaceutical Salts", J. PHARMA. SCI., vol. 66, 1977, pages 1, XP002675560, DOI: doi:10.1002/jps.2600660104
GRANERO GE; AMIDON GL, INTERNAT. J PHARMACEUT., vol. 317, 2006, pages 14 - 18
HUSSAIN MA ET AL., PHARM RES., vol. 5, 1988, pages 44 - 47
HUSSAIN MA; SHEFTER E, PHARM RES., vol. 5, 1988, pages 113 - 5
L.-H. PAO: "IN VITRO AND IN VIVO EVALUATION OF THE METABOLISM AND PHARMACOKINETICS OF SEBACOYL DINALBUPHINE", DRUG METABOLISM AND DISPOSITION, vol. 33, no. 3, 1 January 2004 (2004-01-01), pages 395 - 402, XP055016079, ISSN: 0090-9556, DOI: 10.1124/dmd.104.002451 *
MAELICKE A ET AL., J MOL NEUROSCI, vol. 40, 2010, pages 135 - 137
ROWE RC, SHESKEY PJ, AND WELLER PJ,: "Handbook of Pharmaceuticals Excipients", 2003, PHARMACEUTICAL PRESS
WANG JHI-JOUNG ET AL: "Ester prodrugs of morphine improve transdermal drug delivery: a mechanistic study", JOURNAL OF PHARMACY AND PHARMACOLOGY, ROYAL PHARMACEUTICAL SOCIETY OF GREAT BRITAIN, GB, vol. 59, no. 7, 1 July 2007 (2007-07-01), pages 917 - 925, XP008088560, ISSN: 0022-3573, DOI: 10.1211/JPP.59.7.0002 *
WELLER S ET AL., CLIN PHARMACOL THER, vol. 54, 1993, pages 595 - 605

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019007441A1 (fr) * 2017-07-04 2019-01-10 山东丹红制药有限公司 Suspension à libération prolongée contenant un ester d'analogue de dézocine et son procédé de préparation
US10744109B2 (en) 2017-07-04 2020-08-18 Shandong Danhong Pharmaceutical Co., Ltd. Sustained release suspension containing dezocine analogue ester and preparation method therefor

Also Published As

Publication number Publication date
GB201019525D0 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
US10507206B2 (en) Oral formulations and lipophilic salts of methylnaltrexone
ES2675316T3 (es) Dosificación farmacéutica que comprende 6'-fluoro-(n-metil- o n,n-dimetil-)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento del dolor neuropático
US5846983A (en) Colonic delivery of nicotine to treat inflammatory bowel disease
TW201114766A (en) Pharmaceutical composition for a hepatitis C viral protease inhibitor
HUT64215A (en) Process for producing two-phase lipophylic medical preparatives
CN102145003A (zh) 含难溶性药物的药用组合物
WO2009069139A1 (fr) Forme posologique fournissant un remplissage liquide contenant de l'ibuprofène
US20180071221A1 (en) Immediate release soluble ibuprofen compositions
TWI660730B (zh) 包含度他雄胺的醫藥組合物及含此組合物的膠囊製劑
US20160151332A1 (en) 4-Methylpyrazole Formulations
JP2020533297A (ja) 医薬組成物
US20040033257A1 (en) Pharmaceutical formulation in a drug delivery system and process for preparing the same
WO2016084099A1 (fr) Composition de capsule en gélatine souple d'agents antitussifs
WO2012066347A1 (fr) Formulations à base d'huile
US20240050416A1 (en) Stable Pharmaceutical Compositions of Apixaban

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11791622

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11791622

Country of ref document: EP

Kind code of ref document: A1